Update shared on30 Jul 2025
Fair value Increased 12%The significant upward revision in Tatva Chintan Pharma Chem’s consensus price target reflects sharply improved net profit margins and a substantial reduction in forward P/E, supporting a new fair value estimate of ₹833.67.
What's in the News
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ended 30 June 2025.
- Received an export order worth USD 3.56 million (INR 299.5 million) for specialty chemicals to be delivered in Q3 FY26.
- Board recommended a final dividend of INR 1 per equity share for FY 2024-25, subject to shareholder approval.
- Q1 2026 results expected to be reported on July 24, 2025.
Valuation Changes
Summary of Valuation Changes for Tatva Chintan Pharma Chem
- The Consensus Analyst Price Target has significantly risen from ₹742.00 to ₹833.67.
- The Net Profit Margin for Tatva Chintan Pharma Chem has significantly risen from 6.56% to 12.44%.
- The Future P/E for Tatva Chintan Pharma Chem has significantly fallen from 63.43x to 29.72x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.